(Q34645599)

3 August 2017

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial (English)

1 reference

3 August 2017

phase III clinical trial

0 references

1 reference

1 reference

metastatic colon cancer

1 reference

1 reference

6

Eric Van Cutsem

0 references

Thierry André

object named as

Thierry André

16

0 references

Dirk Arnold

object named as

Dirk Arnold

3

0 references

Frank Gieseler

1 reference

ORCID Public Data File 2021

author name string

Jaafar Bennouna

1

1 reference

3 August 2017

Javier Sastre

2

1 reference

3 August 2017

Pia Österlund

4

1 reference

3 August 2017

Richard Greil

5

1 reference

3 August 2017

Roger von Moos

7

1 reference

3 August 2017

Jose Maria Viéitez

8

1 reference

3 August 2017

Olivier Bouché

9

1 reference

3 August 2017

Christophe Borg

10

1 reference

3 August 2017

Claus-Christoph Steffens

11

1 reference

3 August 2017

Vicente Alonso-Orduña

12

1 reference

3 August 2017

Christoph Schlichting

13

1 reference

3 August 2017

Irmarie Reyes-Rivera

14

1 reference

3 August 2017

Belguendouz Bendahmane

15

1 reference

3 August 2017

Stefan Kubicka

17

1 reference

3 August 2017

ML18147 Study Investigators

18

1 reference

3 August 2017

16 November 2012

1 reference

Lancet Oncology Commission

3 August 2017

1 reference

3 August 2017

14

1 reference

3 August 2017

29-37

1 reference

3 August 2017

1

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970477-1

7 January 2021

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970477-1

7 January 2021

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970477-1

7 January 2021

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970477-1

7 January 2021

Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970477-1

7 January 2021

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970477-1

7 January 2021

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970477-1

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970477-1

7 January 2021

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970477-1

7 January 2021

Targeted therapies: Goldie-Coldman and bevacizumab beyond disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970477-1

7 January 2021

Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970477-1

7 January 2021

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970477-1

7 January 2021

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970477-1

7 January 2021

Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970477-1

7 January 2021

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970477-1

7 January 2021

Resistance to chemotherapy in cancer: a complex and integrated cellular response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970477-1

7 January 2021

Modes of resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970477-1

7 January 2021

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970477-1

7 January 2021

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970477-1

7 January 2021

10.1016/S1470-2045(12)70477-1

Identifiers

DOI

1 reference

3 August 2017

1 reference